{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:20Z","timestamp":1753868660114,"version":"3.41.2"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"SIRTEX"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Metastatic uveal melanoma is a highly aggressive disease with no standard of care treatment option. A large proportion of patients have liver\u2010only metastatic disease which raises the question if liver\u2010directed therapy can be efficacious in this subpopulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>The study aims to evaluate the safety and efficacy of radiosensitizing chemotherapy in combination with yttrium\u201090 microspheres in patients with uveal melanoma with liver\u2010only metastases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>This single arm, open labeled, non\u2010randomized study enrolled 10 patients with liver\u2010only metastatic uveal melanoma between November 2012 and January 2018. Eligible patients received intrahepatic yttrium\u201090 microspheres followed by intravenous cisplatin (20\u00a0mg\/m<jats:sup>2<\/jats:sup>) for 5\u00a0days. Ten patients were enrolled, but nine patients received treatment who were included in the final analysis with a median follow\u2010up of 30\u00a0months (range 7 to 44). Five (50%) were female, five (50%) had an elevated lactate dehydrogenase (LDH), and one (10%) had prior anti\u2010PD\u20101 therapy. The combination was well tolerated with no greater than or equal to grade 3 toxicity observed. The liver objective response rate (ORR) was 33% (3\/9), the median progression\u2010free survival (PFS) in the liver was 3\u00a0months (95% CI, 3\u2010NA), and the extrahepatic PFS was 3\u00a0months (95% CI, 3\u2010NA). Seventy\u2010eight percent (7\/9) received an immune checkpoint inhibitor on disease progression, with no responses seen. The median overall survival (OS) was 10\u00a0months (95% CI, 7\u2010NA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of cisplatin with yttrium\u201090 microspheres was well tolerated; however, it was associated with intrahepatic disease control of relatively short duration. No responses were seen in patients treated with immune checkpoint inhibitors post\u00a0radioembolization.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1183","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T07:38:07Z","timestamp":1557819487000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A pilot study of intrahepatic yttrium\u201090 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver\u2010only metastases"],"prefix":"10.1002","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5636-6381","authenticated-orcid":false,"given":"Surein","family":"Arulananda","sequence":"first","affiliation":[{"name":"Medical Oncology Unit Austin Health  Heidelberg Victoria Australia"},{"name":"Cancer Immuno\u2010Biology Laboratory Olivia Newton\u2010John Cancer Research Institute  Heidelberg Victoria Australia"},{"name":"School of Cancer Medicine La Trobe University  Bundoora Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit Austin Health  Heidelberg Victoria Australia"},{"name":"Cancer Immuno\u2010Biology Laboratory Olivia Newton\u2010John Cancer Research Institute  Heidelberg Victoria Australia"},{"name":"School of Cancer Medicine La Trobe University  Bundoora Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodie","family":"Palmer","sequence":"additional","affiliation":[{"name":"Cancer Immuno\u2010Biology Laboratory Olivia Newton\u2010John Cancer Research Institute  Heidelberg Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Department of Radiology Austin Hospital  Heidelberg Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles C.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit Austin Health  Heidelberg Victoria Australia"},{"name":"Cancer Immuno\u2010Biology Laboratory Olivia Newton\u2010John Cancer Research Institute  Heidelberg Victoria Australia"},{"name":"School of Cancer Medicine La Trobe University  Bundoora Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Parkville Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cebon","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit Austin Health  Heidelberg Victoria Australia"},{"name":"Cancer Immuno\u2010Biology Laboratory Olivia Newton\u2010John Cancer Research Institute  Heidelberg Victoria Australia"},{"name":"School of Cancer Medicine La Trobe University  Bundoora Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.07.003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11057"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1090"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000242"},{"issue":"3","key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e328334c36e","article-title":"Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome","volume":"20","author":"Schuster R","year":"2010","journal-title":"Melanoma Res"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2472062029"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.7916"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt585"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.11.037"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-0998-z"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.08.015"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000033"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-012-0373-5"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900802620893"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.12.154"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000109"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0606-5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0330"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0066"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000575"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcnr2.1183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T03:53:13Z","timestamp":1694317993000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/cnr2.1183"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1183","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"2019-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1183"}}